Abbott Settles TriCor Patent Spat With Teva

Law360, New York (November 30, 2009, 6:32 PM EST) -- Abbott Laboratories has reached a license agreement with Teva Pharmaceuticals USA Inc., resolving a patent dispute between the companies over Teva's planned generic version of the cholesterol drug TriCor.

In a filing Monday with the U.S. Securities and Exchange Commission, Abbott said it had granted Teva the rights to the 145-milligram dose of TriCor no sooner than March 28, 2011. Under certain unspecified circumstances, Teva may not get rights to the patents until July 1, 2012, the filing says.

The filing does not specify in which...
To view the full article, register now.